AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1869005 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron medication (2 x 1 Aktiferrin comp. Kps. during pregnancy starting from the 22nd week)
Number of subjects: 103
Study 1869005 — intervention group
Group type: COMPARATOR
Intervention: No medication during pregnancy (control group)
Number of subjects: 103
Study 6718333 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (administered intravenously and/or intranasally)
Number of subjects: 27
Study 6718333 — intervention group
Group type: COMPARATOR
Intervention: Control (double blind)
Number of subjects: 27
Study 30260458 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-JTC (Metacognitive Training for Jumping to Conclusions)
Number of subjects: 37
Study 30260458 — intervention group
Group type: COMPARATOR
Intervention: AC (Attention Control)
Number of subjects: 37
Study 30063813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 161
Study 30063813 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 161
Study 30063813 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 161
Study 27411267 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing therapy (observation group, n = 17)
Number of subjects: 34
Study 27411267 — intervention group
Group type: COMPARATOR
Intervention: Ordinary dressing therapy (control group, n = 17)
Number of subjects: 34
Study 27411267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 24842697 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33357
Study 24842697 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33357
Study 24842697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33357
Study 23062629 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail
Number of subjects: 830
Study 23062629 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 830
Study 20394043 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 164
Study 20394043 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 164
Study 22362859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI) 12.5-50 μg
Number of subjects: 0
Study 22362859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI) 3, 6.25, 12.5, 25 and 50 μg
Number of subjects: 0
Study 22362859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol trifenatate (VI)
Number of subjects: 0
Study 22362859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15825065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (2500 ova orally at 2-week intervals for 12 weeks)
Number of subjects: 54
Study 15825065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration at 2-week intervals for 12 weeks)
Number of subjects: 54
Study 15825065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Number of subjects: 54
Study 15825065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova and Placebo
Number of subjects: 54
Study 12614246 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist monotherapy (group 1)
Number of subjects: 151
Study 12614246 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist and chlormadinone acetate (group 2)
Number of subjects: 151
Study 10229436 — intervention group
Group type: EXPERIMENTAL
Intervention: SASSS method for the spine
Number of subjects: 187
Study 10229436 — intervention group
Group type: EXPERIMENTAL
Intervention: BASRI
Number of subjects: 187
Study 10229436 — intervention group
Group type: EXPERIMENTAL
Intervention: New York method for SI joints
Number of subjects: 187
Study 10229436 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsen hip scores
Number of subjects: 187
Study 10229436 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of change
Number of subjects: 187
Study 8657212 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 525
Study 1809525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% vitamin E gel
Number of subjects: 48
Study 1809525 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 48
Study 1809525 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 48
Study 6605713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil, 500 mg twice daily
Number of subjects: 34
Study 6605713 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times daily
Number of subjects: 34
Study 31566281 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound media (listening to music)
Number of subjects: 95
Study 31566281 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual media (watching videos)
Number of subjects: 95
Study 31566281 — intervention group
Group type: COMPARATOR
Intervention: No media distraction (control group)
Number of subjects: 95
Study 27623757 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6 g)
Number of subjects: 12
Study 27623757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28595861 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1246
Study 28595861 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1246
Study 26983039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Tamsulosin plus Finasteride
Number of subjects: 92
Study 26983039 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with Tamsulosin
Number of subjects: 92
Study 23972722 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy salvage radiation therapy (RT)
Number of subjects: 30
Study 23972722 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 30
Study 23972722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy run (DR) treatment plan for 70 Gy
Number of subjects: 30
Study 21122628 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytochemical-enhanced diet (PED)
Number of subjects: 24
Study 21122628 — intervention group
Group type: COMPARATOR
Intervention: Modified Mediterranean-style, low-glycemic-load diet (MED)
Number of subjects: 24
Study 18066684 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency rTMS (110% motor threshold, 1 Hz, 2000 stimuli/day)
Number of subjects: 32
Study 18066684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency priming stimulation (6 Hz, 90% motor threshold, 960 stimuli) followed by low-frequency rTMS (110% motor threshold, 1 Hz, 1040 stimuli/day)
Number of subjects: 32
Study 16644619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ester-C (1000 mg)
Number of subjects: 50
Study 16644619 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic Acid (AA) (1000 mg)
Number of subjects: 50
Study 16644619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ester-C
Number of subjects: 50
Study 16644619 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic Acid (AA)
Number of subjects: 50
Study 12803598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg kg‐1 intravenously
Number of subjects: 41
Study 12803598 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving equal volumes of normal saline
Number of subjects: 41
Study 10662706 — intervention group
Group type: EXPERIMENTAL
Intervention: TPNGLN (0.4 g x kg(‐1) x day(‐1))
Number of subjects: 17
Study 10662706 — intervention group
Group type: EXPERIMENTAL
Intervention: TPNGLN+GH/IGF-I (0.2 IU. kg(‐1). day(‐1) GH and 160 microg x kg(‐1) x day(‐1) IGF-I)
Number of subjects: 17
Study 10662706 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 17
Study 8646806 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + FA (group A)
Number of subjects: 88
Study 8646806 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + FA + MTX (group B)
Number of subjects: 88
Study 2001826 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at night
Number of subjects: 22
Study 2001826 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole every morning
Number of subjects: 22
Study 6354100 — intervention group
Group type: EXPERIMENTAL
Intervention: AF (ADM, 40 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Number of subjects: 119
Study 6354100 — intervention group
Group type: COMPARATOR
Intervention: MF (MMC, 10 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Number of subjects: 119
Study 6354100 — intervention group
Group type: EXPERIMENTAL
Intervention: AF
Number of subjects: 119
Study 6354100 — intervention group
Group type: COMPARATOR
Intervention: MF
Number of subjects: 119
Study 30508988 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (RF lesions performed)
Number of subjects: 30
Study 30508988 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (no RF lesions performed)
Number of subjects: 30
Study 28390208 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual toothbrush
Number of subjects: 28
Study 28390208 — intervention group
Group type: COMPARATOR
Intervention: Interdental brushes (IDBs) plus manual toothbrush
Number of subjects: 28
Study 24697580 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-6-sR (≥ 37,401.36 pg/mL, highest tertile) at Year 16
Number of subjects: 905
Study 24697580 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-6-sR at both time points
Number of subjects: 905
Study 24697580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitioned to a high level of IL-6-sR
Number of subjects: 905
Study 22240336 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 66
Study 22240336 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 66
Study 20575721 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based referral-care management (TBR-CM) intervention with brief motivational telephone sessions
Number of subjects: 169
Study 20575721 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of psychiatric appointment and standard institutional reminders
Number of subjects: 169
Study 18223031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 3849
Study 18223031 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3849
Study 18223031 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 3849
Study 18223031 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone vs Metformin
Number of subjects: 3849
Study 18223031 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone vs Glyburide
Number of subjects: 3849
Study 16009165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (3 mg SC)
Number of subjects: 185
Study 16009165 — intervention group
Group type: COMPARATOR
Intervention: Ganirelix acetate (0.25 mg SC daily)
Number of subjects: 185
Study 12225274 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative information in advertisements
Number of subjects: 1504
Study 12225274 — intervention group
Group type: EXPERIMENTAL
Intervention: Compelling evidence for claims
Number of subjects: 1504
Study 12225274 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicitly reporting quantitative outcomes
Number of subjects: 1504
Study 9990629 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge ICD defibrillation test
Number of subjects: 31
Study 9990629 — intervention group
Group type: COMPARATOR
Intervention: No predischarge ICD defibrillation test
Number of subjects: 31
Study 7781432 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal piezoelectric lithotripsy (EPL)
Number of subjects: 35
Study 7781432 — intervention group
Group type: COMPARATOR
Intervention: Intracorporeal electrohydraulic lithotripsy (EHL)
Number of subjects: 35
Study 2138749 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release carbamazepine
Number of subjects: 114
Study 2138749 — intervention group
Group type: COMPARATOR
Intervention: carbamazepine
Number of subjects: 114
Study 555598 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolair SR (10 mg/kg)
Number of subjects: 8
Study 555598 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur (10 mg/kg)
Number of subjects: 8
Study 30653957 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% once a day (q.d.)
Number of subjects: 756
Study 30653957 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% twice a day (b.i.d.)
Number of subjects: 756
Study 30653957 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day (b.i.d.)
Number of subjects: 756
Study 28732822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical coverage at admission
Number of subjects: 179
Study 28732822 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam monotherapy continued
Number of subjects: 179
Study 26410680 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation (within 12 hours)
Number of subjects: 776
Study 26410680 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed intubation
Number of subjects: 776
Study 26410680 — intervention group
Group type: COMPARATOR
Intervention: Never intubated
Number of subjects: 776
Study 26410680 — intervention group
Group type: COMPARATOR
Intervention: ICUs with lowest frequency of early intubation
Number of subjects: 776
Study 23403074 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams Talking Trials (TTT) Workshop
Number of subjects: 22
Study 20627440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 218
Study 20627440 — intervention group
Group type: COMPARATOR
Intervention: Prescriptive advice
Number of subjects: 218
Study 18616391 — intervention group
Group type: EXPERIMENTAL
Intervention: Field experiments
Number of subjects: 0
Study 18616391 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized experiments
Number of subjects: 0
Study 18616391 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression discontinuity designs
Number of subjects: 0
Study 18616391 — intervention group
Group type: EXPERIMENTAL
Intervention: Short interrupted time series
Number of subjects: 0
Study 18616391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized experiments
Number of subjects: 0
Study 17522328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis antigens delivered by adenylate cyclase
Number of subjects: 119
Study 17522328 — intervention group
Group type: COMPARATOR
Intervention: Native tuberculosis antigens (without adenylate cyclase delivery)
Number of subjects: 119
Study 17522328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma interferon responses to tuberculosis antigens (with or without delivery by adenylate cyclase)
Number of subjects: 119
Study 17522328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo responses to tuberculosis antigens delivered by adenylate cyclase
Number of subjects: 119
Study 15172406 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol intake (1 to 10 drinks/week)
Number of subjects: 2231
Study 15172406 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>10 drinks/week)
Number of subjects: 2231
Study 15172406 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption reported three months after MI
Number of subjects: 2231
Study 11840581 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg/kg and atropine 0.01 mg/kg
Number of subjects: 40
Study 11840581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9806672 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 20
Study 9806672 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 20
Study 7625120 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 RIA antigen unit dose
Number of subjects: 195
Study 7625120 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 195
Study 1978161 — intervention group
Group type: EXPERIMENTAL
Intervention: daily injections of growth hormone (rhGH) at 30 IU/m2 per week
Number of subjects: 41
Study 1978161 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 41
Study 321723 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin
Number of subjects: 0
Study 321723 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 321723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 0
Study 31995239 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of estimated energy needs
Number of subjects: 35
Study 31995239 — intervention group
Group type: COMPARATOR
Intervention: 40% of estimated energy needs
Number of subjects: 35
Study 31995239 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time energy flow rate (high tertile)
Number of subjects: 35
Study 31995239 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time energy flow rate (middle tertile)
Number of subjects: 35
Study 31995239 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper median of real-time energy flow rate
Number of subjects: 35
Study 30137394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to social adverse childhood experiences (ACEs)
Number of subjects: 2120
Study 30137394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to community violence (for women)
Number of subjects: 2120
Study 30137394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to peer violence (for men)
Number of subjects: 2120
Study 27678453 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPHA + CTCs
Number of subjects: 0
Study 27678453 — intervention group
Group type: COMPARATOR
Intervention: ALPHA
Number of subjects: 0
Study 26410565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinochill
Number of subjects: 70
Study 26410565 — intervention group
Group type: COMPARATOR
Intervention: Blanketrol
Number of subjects: 70
Study 26410565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oxytocin (10, 40, or 80 U)
Number of subjects: 1798
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 1798
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 1798
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic white ethnicity
Number of subjects: 1798
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 1798
Study 23507549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 1798
Study 21709202 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA404 (vadimezan) 1800 mg/m2, given intravenously once every 3 weeks for six cycles followed by maintenance ASA404
Number of subjects: 1299
Study 21709202 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given intravenously once every 3 weeks for six cycles followed by maintenance placebo
Number of subjects: 1299
Study 21709202 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA404 (vadimezan) 1800 mg/m2
Number of subjects: 1299
Study 21709202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1299
Study 19545579 — intervention group
Group type: EXPERIMENTAL
Intervention: Game of Dice Task (GDT)
Number of subjects: 44
Study 19545579 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (IGT)
Number of subjects: 44
Study 16181713 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated lateral-reaching tasks
Number of subjects: 38
Study 12527976 — intervention group
Group type: COMPARATOR
Intervention: 0 g glucose (PLAC)
Number of subjects: 9
Study 12527976 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose (LOW)
Number of subjects: 9
Study 12527976 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose (MED)
Number of subjects: 9
Study 12527976 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g glucose (HIGH)
Number of subjects: 9
Study 10583700 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 30 mg/day plus Piracetam 3200 mg/day
Number of subjects: 30
Study 10583700 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 30 mg/day plus Placebo
Number of subjects: 30
Study 8916658 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 54
Study 8916658 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 54
Study 8916658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 1988321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1 g daily for 4 days)
Number of subjects: 30
Study 1988321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, q.i.d. for 4 days)
Number of subjects: 30
Study 6874891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (5 mg each) at 12-h intervals for 4 injections
Number of subjects: 74
Study 6874891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6874891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 74
Study 3890241 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage (PTBD) for 13.8 +/- 5.8 days
Number of subjects: 30
Study 3890241 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 30
Study 3890241 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 30
Study 31563133 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 107
Study 31563133 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP)
Number of subjects: 107
Study 31758633 — intervention group
Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 971
Study 31758633 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 971
Study 28669789 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed interactive video-based instruction (IVBI)
Number of subjects: 50